Leuven Belgium, March 18th, 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, has appointed Dr. Lode Debrabandere as Chief Business Officer. Based on the East Coast of the Unites States, Dr. Debrabandere will be responsible for reMYND’s business development activities and global strategy and will lead the expansion of the Company’s network internationally.

Dr. Debrabandere joins reMYND with over 25 years of experience in senior positions across the biotechnology and pharmaceutical sectors. He spent ten years at Osiris Therapeutics, first as Vice President and General Manager of the Therapeutics Business Unit, where he was responsible for the development of Prochymal® (remestemcel-L), the world's first approved stem cell drug for graft versus host disease. In 2012, he was promoted to Chief Operating Officer before becoming President and Chief Executive Officer in 2013

Previously, Dr. Debrabandere served as Vice President of Global Marketing at Bristol Myers Squibb where he led the Neuroscience Business Unit and was the Global Brand Leader for Abilify™. Lode has also served as Chief Executive Officer of Aziyo Biologics and founded 3RBiomed and Amynas. He began his career in Clinical Operations and Marketing at UCB, based in Belgium.

Dr. Debrabandere holds a Pharm.D in Pharmaceutical Sciences, a Ph.D in Toxicology and an MBA from the University of Leuven.

Dr. Lode Debrabandere, Chief Business Officer of reMYND commented: “I am thrilled to join reMYND and implement our international growth strategy.  reMYND has the leadership team, advanced pipeline and strategic determination to bring first-in-class therapeutics to patients suffering from debilitating diseases, like Alzheimer’s, Diabetes, Huntington’s and ALS”. 

Koen De Witte, Managing Director of reMYND commented: “Lode’s rich and varied experience as COO and CEO of various global biotech & pharmaceutical companies will be invaluable to realising reMYND’s growth well beyond business development and stepping up our international network.”

 

 

About reMYND

reMYND is a clinical stage company developing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug discovery platform, which enables the identification of novel mechanisms-of-action, targets and first-in-class small molecules.

reMYND’s most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimer’s, which entered the clinic in Q4 2020. In animal models it has shown to produce an acute response, restoring synaptic plasticity, a process central in the disease cascade leading to neuronal demise and build-up of plaques and tangles. The company is also developing a treatment for diabetes, ReS39. Animal models have demonstrated the compound’s efficacy to increase endogenous insulin production capacity with a sustained and durable effect on blood glucose levels and end-organ protection.

Other treatments for major health challenges are being explored using reMYND’s discovery platform, with a focus on mitochondrial dysfunction in central nervous system (CNS) disorders.

In addition, reMYND has a dedicated Contract Research Organization (CRO), which focuses on CNS disorders. The team helps clients to assess the pharmacokinetics, pharmacodynamics and efficacy of their experimental treatments in reMYND’s proprietary animal models. The CRO has a global client base, including the US, Europe and Japan.

reMYND was founded in 2002 as a spin-off from the University of Leuven, and has been substantially supported by grants from VLAIO/IWT (Flanders, Belgium). Find out more at https://www.remynd.com.

Categories: Corporate